Description

Simple

Clinical

Overview

Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile.

Pharmacology

Indication

For the the treatment of depressive fatigue in convalescence and other debilitated states as well as in the treatment of depressive day-time fatigue, lack of concentration and lethargy.

Pharmacodynamic

Fencamfamine increases drive and mental alertness and an elevation of mood and a general feeling of well-being. It is a central nervous system stimulant, which increases locomotor activity.

Mechanism of action

Fencamfamine acts as an indirect dopamine agonist. It releases dopamine by a similar mechanism to amphetamines, but is 10x less potent than dexamphetamine at producing this effect. The drug seems to inhibit the dopamine transporter (DAT) that removes dopamine from the synapses. This inhibition of DA... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Overdosage is characterised by nausea, agitation and restlessness, dryness of the mouth, dizziness and tremor. In gross overdosage the above symptoms may also be associated with dyspnoea, tachycardia, disorientation and convulsions.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Fencamfamin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Fencamfamin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Fencamfamin is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Fencamfamin is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Fencamfamin is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Fencamfamin is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Fencamfamin is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Acepromazine
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Aceprometazine.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Fencamfamin.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Fencamfamin.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Fencamfamin may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Fencamfamin.
Adipiplon
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Adipiplon.
Agomelatine
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Agomelatine.
Ajulemic acid
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Fencamfamin.
Alaproclate
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Alaproclate.
Alcuronium
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Alcuronium.
Alfaxalone
The risk or severity of adverse effects can be increased when Fencamfamin is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Fencamfamin.
2 References
  1. 1 . DeLucia R, Planeta CS: Fencamfamine. Gen Pharmacol. 1990;21(2):161-3.PubMed: 1970543
  2. 2 . Link Link